iTeos to Present at the Jefferies Virtual Healthcare Conference
iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:00 a.m. ET. A live webcast will be available on the company's website, with an archived replay for 30 days. iTeos focuses on developing innovative immuno-oncology therapeutics, including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are undergoing clinical trials showcasing preliminary clinical activity in adult patients with advanced solid tumors.
- None.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:00 a.m. ET.
A live webcast of the presentation will be available on the Investors section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of cancer immunology and immunosuppressive pathways to design novel product candidates with the potential to fully restore the immune response against cancer. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1/2a clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a next-generation adenosine A2A receptor antagonist tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity in the dose escalation portion of the trial. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contacts:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com
Media Contacts:
media@iteostherapeutics.com
FAQ
When will iTeos Therapeutics present at the Jefferies Virtual Healthcare Conference?
What is the focus of iTeos Therapeutics?
What are the main product candidates of iTeos Therapeutics?
What is EOS-448?
What is inupadenant?
Where can I watch the presentation from iTeos Therapeutics?
How long will the replay of iTeos Therapeutics' presentation be available?
